Mizuho analyst Uy Ear downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Buy to Neutral with a price target of $25.00 (from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change Downgrades

Acadia Pharmaceuticals (ACAD) Stock Selloff Is Over Done Says UBS, 'the level of sell-off is surprising to us'March 12, 2024 4:07 PM Acadia Pharma (ACAD) to stop pimavanserin trials after failureMarch 12, 2024 12:52 PM Acadia Pharmaceuticals (ACAD) PT Lowered to $30.19 at CitiMarch 12, 2024 3:57 AM Acadia Pharmaceuticals (ACAD) PT Lowered to $39 at JMP SecuritiesMarch 12, 2024 2:49 AM Mizuho Downgrades Acadia Pharmaceuticals (ACAD) to Neutral, 'Disappointing ADVANCE-2 Data'March 12, 2024 2:23 AM After-hours movers: Oracle surges, Acadia Pharma slumpsMarch 11, 2024 4:49 PM Acadia Pharma (ACAD) to Resume Trading at 4:35 p.m., Study Did Not Meet Primary EndpointMarch 11, 2024 4:10 PM Form 8-K ACADIA PHARMACEUTICALS For: Mar 11March 11, 2024 4:06 PM Acadia Pharma (ACAD) Reports Top-Line Results from Phase 3 ADVANCE-2 Trial of PimavanserinMarch 11, 2024 4:05 PM Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of SchizophreniaMarch 11, 2024 4:05 PM Acadia Pharma (ACAD) Halted, News PendingMarch 11, 2024 4:01 PM